retatrutide ly3437943 parkinson's disease clinical trial LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to proof of concept: Cell Metabolism A Study of Retatrutide (LY3437943)

In a Phase 2 clinical trial published in 2023 in the New England Journal of Medicine (Jastreboff et al.), participants receiving the highest dose of retatrutide lost up to approximately 24% of their body weight over 48 weeks a notably greater reduction than observed with currently approved agents

I would have thought that the pills would have higher side effects, but its really pretty similarand its no worse than with the shots, Dr

Be cautious of rapid weight loss or unmanaged side effects

99%+ purity, US manufactured, COA included

Vad r Retatrutide & HGH

According to the Mounjaro PIL, the pen should be removed from the refrigerator and allowed to reach room temperature for approximately 30 minutes before injecting